Taspoglutida Uses, Dosage, Side Effects and more
Taspoglutida is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche. In September 2010 Roche halted Phase III clinical trials due to incidences of serious hypersensitivity reactions and gastrointestinal side effects. As of May 2013 no new trials had been registered.
| Trade Name | Taspoglutida |
| Generic | Taspoglutide |
| Taspoglutide Other Names | Taspoglutida, Taspoglutide, Taspoglutidum |
| Type | |
| Formula | C152H232N40O45 |
| Weight | Average: 3339.763 Monoisotopic: 3337.70952553 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
